Cobra Biologics and BioCancell have entered an agreement for the manufacture of BioCancell’s BC-821 cancer drug for clinical trials. The Phase I trial, scheduled to begin in 2015, will examine the use of BC-821 as a treatment for several cancer indications such as non-small-cell lung carcinoma, ovarian cancer, glioblastoma and liver metastasis.   Cobra will provide GMP manufacture and aseptic fill/finish of BC-821 plasmid DNA, before releasing it for clinical trials. Cobra’s DNA programs offer f...